Top

Cancer Causes & Control

Published in:

01-05-2017 | Original paper

A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women

Authors: Traci N. Bethea, Julie R. Palmer, Lucile L. Adams-Campbell, Lynn Rosenberg

Published in: Cancer Causes & Control | Issue 5/2017

Abstract

Purpose

Extensive data in White women have linked oral contraceptive use, tubal ligation, and parity to reduced risk of ovarian cancer; results on postmenopausal female hormone use are mixed. Few studies, all of which are case–control studies, have been undertaken among Black women. The aim of the present study was to prospectively assess associations of reproductive factors and exogenous hormones with ovarian cancer among Black women.

Methods

During follow-up from 1995 to 2013 in the Black Women’s Health Study, a prospective cohort study, 115 incident cases of ovarian cancer were identified. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the relation of the factors of interest to risk of ovarian cancer, with control for covariates.

Result

Oral contraceptive use was inversely associated with ovarian cancer risk: The HR for ≥10 years of use relative to <1 year was 0.50 (95% CI 0.30–0.98). For postmenopausal female hormone use, the HRs for ever use of estrogen with progestin and of estrogen alone were 1.37 (0.73–2.55) and 1.66 (0.90–3.07), respectively. The HRs for parity and tubal ligation were below 1.0, but were not statistically significant.

Conclusion

Overall, the findings indicate that the relation of reproductive factors and exogenous hormone use to risk of ovarian cancer is similar among Black and White women. The results on estrogen-only supplements and estrogen with progestin supplements add to evidence from Whites, indicating that use of hormone supplements may be associated with increased risk of ovarian cancer.

Chumlea WC, Schubert CM, Roche AF et al (2003) Age at menarche and racial comparisons in US girls. Pediatrics 111:110–113CrossRefPubMed

Martin JA, Osterman MJ, Centers for Disease C, Prevention (2013) Preterm births—United States, 2006 and 2010. MMWR Suppl. 62:136–138

Centers for Disease C, Prevention (2013) Progress in increasing breastfeeding and reducing racial/ethnic differences-United States, 2000–2008 births. MMWR Morb Mortal Wkly Rep 62:77–80

Daniels K, Mosher WD (2013) Contraceptive methods women have ever used: United States, 1982–2010. Natl Health Stat Report 62:1–15

Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 5:13CrossRefPubMedPubMedCentral

McLemore MR, Miaskowski C, Aouizerat BE, Chen LM, Dodd MJ (2009) Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs. 32:281–288 quiz 9–90 CrossRefPubMedPubMedCentral

Chowdhury R, Sinha B, Sankar MJ et al (2015) Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr 104:96–113CrossRefPubMedPubMedCentral

Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B (2013) Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr 98:1020–1031CrossRefPubMedPubMedCentral

Wu AH, Pearce CL, Tseng CC, Pike MC (2015) African Americans and hispanics remain at lower risk of ovarian cancer than non-hispanic whites after considering nongenetic risk factors and oophorectomy rates. Cancer Epidemiol Biomark Prev 24:1094–1100CrossRef

10.

Terry KL, Karageorgi S, Shvetsov YB et al (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila) 6:811–821CrossRef

11.

Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:1075–1084CrossRefPubMed

12.

Lee AW, Ness RB, Roman LD et al (2016) Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Obstet Gynecol 127:828–836CrossRefPubMed

13.

Trabert B, Wentzensen N, Yang HP et al (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107:1181–1187CrossRefPubMedPubMedCentral

14.

John EM, Whittemore AS, Harris R, Itnyre J (1993) Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case–control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85:142–147CrossRefPubMed

15.

Hoyo C, Berchuck A, Halabi S et al (2005) Anthropometric measurements and epithelial ovarian cancer risk in African–American and White women. Cancer Causes Control 16:955–963CrossRefPubMed

16.

Ness RB, Grisso JA, Klapper J, Vergona R (2000) Racial differences in ovarian cancer risk. J Natl Med Assoc 92:176–182PubMedPubMedCentral

17.

Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM (2009) Ovarian cancer risk factors in African-American and white women. Am J Epidemiol 170:598–606CrossRefPubMedPubMedCentral

18.

Moorman PG, Alberg AJ, Bandera EV et al (2016) Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 26:654–662CrossRefPubMed

19.

Schildkraut JM, Alberg AJ, Bandera EV et al (2014) A multi-center population-based case–control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer 14:688CrossRefPubMedPubMedCentral

20.

Rosenberg L, Adams-Campbell L, Palmer JR (1995) The Black Women’s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50:56–58

21.

Rosenberg L, Palmer JR, Rao RS, Adams-Campbell LL (1999) Risk factors for coronary heart disease in African American women. Am J Epidemiol 150:904–909CrossRefPubMed

22.

NCHS (2013) National Death Index user’s guide. In: National Center for Health Statistics CfDCaP, U.S. Department of Health and Human Services, ed. Hyattsville, MD

23.

Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN (2003) Pathology and classification of ovarian tumors. Cancer 97:2631–2642CrossRefPubMed

24.

Rosen DG, Yang G, Liu G et al (2009) Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed) 14:2089–2102CrossRef

25.

Carter-Nolan PL, Adams-Campbell LL, Makambi K, Lewis S, Palmer JR, Rosenberg L (2006) Validation of physical activity instruments: Black Women’s Health Study. Ethn Dis 16:943–947PubMed

26.

Therneau TM (1996) Extending the Cox Model. Technical Report Series: Section of Biostatistics. Rochester, MN: Mayo Clinic. pp 1–63

27.

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRef

28.

Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842CrossRefPubMedCentral

29.

Rice MS, Hankinson SE, Tworoger SS (2014) Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies. Fertil Steril 102(192–8):e3

30.

Rice MS, Murphy MA, Vitonis AF et al (2013) Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case–Control Study. Int J Cancer 133:2415–2421CrossRefPubMedPubMedCentral

31.

Gaitskell K, Green J, Pirie K, Reeves G, Beral V, Million Women Study C (2016) Tubal ligation and ovarian cancer risk in a large cohort: substantial variation by histological type. Int J Cancer 138:1076–1084CrossRefPubMed

32.

Ness RB, Grisso JA, Klapper J et al (2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 152:233–241CrossRefPubMed

33.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94:32–38CrossRefPubMed

34.

Quirk JT, Natarajan N (2005) Ovarian cancer incidence in the United States 1992–1999. Gynecol Oncol 97:519–523CrossRefPubMed

35.

Gershenson DM (2013) The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 33:e195–e199CrossRef

36.

Sieh W, Salvador S, McGuire V et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42:579–589CrossRefPubMedPubMedCentral

37.

Fortner RT, Ose J, Merritt MA et al (2015) Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. Int J Cancer 137:1196–1208CrossRefPubMed

38.

Gaitskell K, Green J, Pirie K, Reeves G, Beral V (2014) Parity and ovarian cancer in the Million Women Study: variation by histological subtype. J Epidemiol Community Health 68:A15–A16CrossRef

Title: A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women
Authors: Traci N. Bethea
Julie R. Palmer
Lucile L. Adams-Campbell
Lynn Rosenberg
Publication date: 01-05-2017
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 5/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-016-0840-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2017

Hormonal and reproductive factors and the risk of ovarian cancer

Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women

Epidemiologic paradigms for progress in ovarian cancer research

Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future

Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles

Keynote webinar | Spotlight on antibody–drug conjugates in cancer